Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital

Key Points

• D. Boral Capital has reiterated a buy rating for Coya Therapeutics (NASDAQ:COYA) with a price target of $18.00, suggesting a potential upside of 169.66% from its previous close.
• Despite the positive ratings from several firms, Coya Therapeutics reported a loss of $0.36 per share for the last quarter, missing analysts' expectations.
• 39.75% of Coya Therapeutics' stock is owned by institutional investors, with notable increases in holdings from firms like DME Capital Management LP and Jane Street Group LLC.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $18.00 target price on the stock. D. Boral Capital's target price would suggest a potential upside of 187.59% from the company's previous close.

A number of other research firms also recently commented on COYA. Lake Street Capital started coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They set a "buy" rating and a $16.00 price objective for the company. Chardan Capital reissued a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, August 25th. Finally, Wall Street Zen downgraded shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Coya Therapeutics has a consensus rating of "Buy" and a consensus price target of $16.50.

Coya Therapeutics Trading Down 1.7%

Shares of COYA stock traded down $0.11 during trading hours on Thursday, hitting $6.26. 78,833 shares of the company were exchanged, compared to its average volume of 76,596. The business has a 50 day moving average of $6.22 and a two-hundred day moving average of $6.07. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24. The company has a market capitalization of $104.68 million, a PE ratio of -5.02 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.78 million. On average, research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently modified their holdings of the stock. DME Capital Management LP lifted its stake in shares of Coya Therapeutics by 29.2% during the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock worth $9,434,000 after buying an additional 372,414 shares during the last quarter. CM Management LLC lifted its stake in shares of Coya Therapeutics by 25.0% during the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock worth $1,294,000 after buying an additional 40,000 shares during the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of Coya Therapeutics during the 1st quarter worth about $1,083,000. Northern Trust Corp lifted its stake in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after buying an additional 3,099 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock worth $169,000 after buying an additional 13,176 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.